Clinical Trial Search

Primary: Haemodynamic Parameters at the Time of Emergence and Postextubation — 128.55; 132.34; 132.63; 134.29 mm Hg

Primary: Change in Plasma LDL Cholesterol — -0.1 mmol/L

Primary: Number of Participants With Selected Gastrointestinal Disorders up to 24 Weeks — 0; 0; 0; 0 Participants

Primary: Percentage of Participants Who Had an ACT Total Score >=20 or an Improvement of More Than 3 Points in ACT During the 24-week Treatment Period — 99.2; 94.3 Percentage of…

Primary: Number of Participants With Complete Closure of the Index Ulcer — 19 Participants

Primary: Glycosylated Hemoglobin A1c (HbA1c) — 6.78 percentage of <HbA1c>

Primary: Clinical Examination — 30; 30 Participants

Primary: Incidence of SCC — 3.1; 0.4 percentage of subjects

Primary: Percentage of Participants Achieving 100% Improvement From Baseline in Psoriasis Area and Severity Index (PASI 100) — 41.3; 24.9 percentage of participants — p=<0.001

Primary: Numeric Rating Scale Pain Scores — 3.0; 0 score on a scale — p=0.0011

Primary: Change From Baseline on Symptoms of Depression Questionnaire (SDQ) — 3.7; 3.7; 3.5; 3.5 score on a scale — p=0.46

Primary: Percentage of Correct Inhibition in Participants Assessed With the Go-No go Task — 79.08; 79.43; 77.98; 78.24 percent correct inhibition

Primary: Nausea 100 mm Visual Analogue Scale (VAS) — 23; 19; 42 units on a scale

Primary: Number of Participants With Surgical Site Infections — 0; 5 Participants — p=0.025

Primary: Change From Baseline to Month 6 in CD4+ Naive T Cells (CCR7+ CD45RA+) — 404.4; 3.4; 7.6; 4.8 cells/uL